Soluble Urokinase Plasminogen Activator Receptor (suPAR)
Soluble circulating form of uPAR shed from myeloid cells (neutrophils, monocytes) during persistent innate immune activation.
Standard vs. Optimal Reference Rangesng/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<3.0 ng/mL
General reference distribution across unselected commercial populations.
<2.0 ng/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds beta-3 integrins on renal podocytes, triggering foot process effacement and driving proteinuria and focal segmental glomerulosclerosis.
Differential Diagnosis
Elevated Levels (suPAR High)
- •Chronic active immune activation and systemic inflammaging
- •Progressive chronic kidney disease and FSGS
- •Severe septic shock
Low Levels (suPAR Low)
- •Low basal myeloid immune activation (<2.0 ng/mL)
- •Optimal renal podocyte integrity
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for suPAR
- Targeted organ system imaging or functional dynamic testing related to chronic innate immune system activation
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Soluble Urokinase Plasminogen Activator Receptor - The New England Journal of Medicine (2021). PMID: 33990124
- [2]suPAR Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Soluble Urokinase Plasminogen Activator Receptor (suPAR) into overall healthspan optimization.